<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1222">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108846</url>
  </required_header>
  <id_info>
    <org_study_id>S-CitAD</org_study_id>
    <nct_id>NCT03108846</nct_id>
  </id_info>
  <brief_title>Escitalopram for Agitation in Alzheimer's Disease</brief_title>
  <acronym>S-CitAD</acronym>
  <official_title>Escitalopram for Agitation in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of escitalopram for
      agitation in Alzheimer's dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to examine the efficacy and safety of escitalopram as treatment for
      agitation in Alzheimer's dementia (AD) patients. Participants with clinically significant
      agitation, and their caregiver(s), will receive a structured psychosocial intervention.
      Participants not showing a response three weeks later will be randomized 1:1 to escitalopram
      (up to 15 mg/day) or a matching placebo. Participants will receive study drug for 12 weeks,
      with in-person visits at weeks 3, 6, 9, and 12, and with telephone contacts between in-person
      visits. Following the 12-week study treatment period, participants will be followed for
      another 12 weeks without receiving study drug. Participants who do show a response to the
      psychosocial intervention will not be randomized to study drug but will be followed for the
      24-week follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Over-encapsulation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>mADCS-CGIC</measure>
    <time_frame>after 12 weeks</time_frame>
    <description>Clinical Global Impression of Change</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-3 capsules each containing placebo only once per day in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>5-15 mg/day (target: 15mg/day if tolerated)</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Masked placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable or known Alzheimer's Disease

          -  Agitation for which treatment is suitable

        Exclusion Criteria:

          -  Major depressive episode
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>109 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Lyketsos, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Shade, JD</last_name>
    <phone>4109558175</phone>
    <email>dshade@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Ehrhardt, MD</last_name>
    <phone>4109558175</phone>
    <email>sehrhar6@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>April 6, 2017</firstreceived_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>JHSPH Center for Clinical Trials</investigator_affiliation>
    <investigator_full_name>Dave Shade</investigator_full_name>
    <investigator_title>Director, S-CitAD Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Agitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

